Remission of disseminated cancer after systemic oncolytic virotherapy

Mayo Clinic Proceedings

Volumn 89, Issue 7, 2014, Pages 926-933

  Russell, Stephen J ^a   Federspiel, Mark J ^a   Peng, Kah Whye ^a   Tong, Caili ^a   Dingli, David ^a   Morice, William G ^a   Lowe, Val ^a   O'Connor, Michael K ^a   Kyle, Robert A ^a   Leung, Nelson ^a   Buadi, Francis K ^a   Rajkumar, S Vincent ^a   Gertz, Morie A ^a   Lacy, Martha Q ^a   Dispenzieri, Angela ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LENALIDOMIDE; M PROTEIN; POMALIDOMIDE; RADIOACTIVE IODINE; THALIDOMIDE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER REGRESSION; CASE REPORT; DIAGNOSTIC IMAGING; DRUG MEGADOSE; FEMALE; GENE EXPRESSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; MULTIPLE MYELOMA; MYELOMA; NON INVASIVE PROCEDURE; ONCOLYTIC VIROTHERAPY; PLASMA CELL; PLASMACYTOMA; PLASMACYTOSIS; REMISSION; TISSUE CULTURE;

AGED; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MEASLES VIRUS; MIDDLE AGED; MULTIPLE MYELOMA; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 84904744363     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2014.04.003     Document Type: Article

References (20)

1. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658-670.
2. Vacchelli E, Eggermont A, Sautès-Fridman C, et al. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology. 2013; 2(6):e24612.
3. Tong AW, Senzer N, Cerullo V, Templeton NS, Hemminki A, Nemunaitis J. Oncolytic viruses for induction of anti-tumor immunity. Curr Pharm Biotechnol. 2012;13(9):1750-1760.
4. Kyle RA, Rajkumar SV. An overview of the progress in the treatment of multiple myeloma. Exp Rev Hematol. 2014;7(1):5-7.
5. Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood. 2004;103(5):1641-1646.
6. Bellini WJ, Rota JS, Rota PA. Virology of measles virus. J Infect Dis. 1994;170(suppl 1):S15-S23.
7. Myers RM, Greiner SM, Harvey ME, et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther. 2007;82(6):700-710.
8. Ong HT, Timm MM, Greipp PR, et al. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol. 2006;34(6):713-720.
9. Ong HT, Hasegawa K, Dietz AB, Russell SJ, Peng KW. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther. 2007;14(4): 324-333.
10. Liu C, Russell SJ, Peng KW. Systemic therapy of disseminated myeloma in passively immunized mice using measles virusinfected cell carriers. Mol Ther. 2010;18(6):1155-1164.
11. Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma. ClinicalTrials.gov Identifier: NCT00450814. ClinicalTrials.gov website. http://clinicaltrials.gov/show/ NCT00450814%20MC038C%20P30CA015083%20MC038C%2006-005263%20NCI-2009- 01194%20NCT00450814. Updated March 20, 2014. Accessed April 14, 2014.
12. Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88(4):360-376.
13. Rajkumar SV, Jacobus S, Callander NS, et al; Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial [published correction appears in Lancet Oncol. 2010;11(1):14]. Lancet Oncol. 2010; 11(1):29-37.
14. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23(7):1337-1341.
15. Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477(7362):99-102.
16. Power AT, Wang J, Falls TJ, et al. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther. 2007;15(1):123-130.
17. Alcayaga-Miranda F, Cascallo M, Rojas JJ, Pastor J, Alemany R. Osteosarcoma cells as carriers to allow antitumor activity of canine oncolytic adenovirus in the presence of neutralizing antibodies. Cancer Gene Ther. 2010;17(11):792-802.
18. Guo ZS, Parimi V, O'Malley ME, et al. The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host. Gene Ther. 2010;17(12):1465-1475.
19. Berry LJ, Au GG, Barry RD, Shafren DR. Potent oncolytic activity of human enteroviruses against human prostate cancer. Prostate. 2008;68(6):577-587.
20. Bailey K, Kirk A, Naik S, et al. Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters. Plos One. 2013;8(9):e73759.